Category Innovation/ R&D

WHO Director Advocates Strong Health Systems, Warns Against Profit-Oriented Mechanisms

The World Health Assembly opened today with World Health Organization Director General Margaret Chan repeating that this year has a record number of agenda items and over 3,000 participants. She slapped at profit-seeking mechanisms leading to "slow-motion disasters," which put economic interests above concerns about well-being. In particular, she underlined the lack of research and development for antimicrobial treatments and the rise of chronic non-communicable diseases.

Can Patents Ever Be “Ever-Greened”? The Answer…They Are “Never-Greened”

“Ever-Greening of Patents” has been an expression that has been extensively used in debates related to the global pharmaceutical industry at least since the last two decades. Interestingly, this term has never been statutorily defined and hence has been applied most freely by professionals, policy makers and politicians alike. It would be appropriate to objectively examine whether patents in any jurisdiction can ever be “ever-greened”. A fitting initiation to this debate is the very concept of what a patent is from the very first principles, writes Prabuddha Ganguli.

Innovation And Access: Fission Or Fusion? Interview with David Taylor, Professor of Pharmaceutical and Public Health Policy, University College London, UK

In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with David Taylor, Professor of Pharmaceutical and Public Health Policy, University College London, UK.

Public Health Advocates Urge WHO Action On Alternative R&D Financing

Public health advocates last week told World Health Organization delegates they must act quickly to save the lives of poor populations suffering from less common diseases for which there is no research and development funding. Nongovernmental organisations showed up to a WHO meeting on the issue to urge on delegates, even holding a public demonstration in front of the UN, but there was concern afterward at the little progress made.

As Patients Wait, WHO Members Chip Away At Decision On Medical R&D Funding

A number of World Health Organization member states attended a meeting last week aimed finding ways to sustainably finance research and development for medical products, especially those for poor populations lacking means to pay high prices. According to the outcome document and a WHO official, they heard many viewpoints from experts and made progress but much was left for the World Health Assembly later this month.

MSF Issues In-Depth Report On R&D And Drug Prices

Médecins Sans Frontières (MSF, Doctor Without Borders) today announced a report detailing what it calls failings in the current system for developing new drugs in ways that all patients can afford and access, and providing proposed policy options for addressing the problems.

Special Report: The Battle For Biosimilars In India

[story updated] Biosimilar drugs hold out big opportunities for India’s drug companies. But the future is fraught with challenges. One key challenge is regulations.

What does this mean for countries like India, an emerging market for biosimilars? How will the evolving global regulatory environment on biosimilars impact patients?

Last month, both these questions came to the fore as the battle over biosimilars moved centre stage in this country in the wake of an interim order by the Delhi High Court, and then another decision by a Division Bench of the same court which took a different view.

Measure Allowing Federal Courts To Handle Trade Secrets Claims Clears US Congress

Legislation authorising federal courts to hear cases involving theft of trade secrets passed the US House of Representatives on 27 April and is now headed for an expected signature by President Barack Obama. Final enactment of the “Defend Trade Secrets Act of 2016” (DTSA), along with the 14 April adoption by the European Parliament of the EU Trade Secrets Directive, boosts protections on both sides of the Atlantic but not uniformly, intellectual property lawyers said.

Surprise! Much Work Being Done On Transparency Of Patents On Medicines

James Love writes: In a recent paper by Reed F. Beall and Amir Attaran [KEI's April 12, 2016 comment here: http://www.keionline.org/node/2467], and in the WIPO seminar discussions about the paper, the authors have held themselves out as more or less lonely voices calling for transparency of patent landscapes on essential medicines. This surprised and offended the many people who have not only been concerned about the lack of transparency on patent landscapes, but have been doing most of the work in digging out the facts, and/or proposing remedies.